Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and PK of CBP-174 in Healthy Subjects
NCT04811469Phase 1Completed
- Sponsor
- Connect Biopharma
- Start
- May 2021
- Primary completion
- May 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial in atopic dermatitis (AD) and pruritus comparing CBP-174 with Placebo (2 arms). Primary endpoints: Incidence and Severity of Adverse Events and Serious Adverse Events, Change in Vital Signs and 7 more. Started May 2021; status: completed.
02
Drugs
CBP-174
03
Conditions
atopic dermatitis (AD)pruritus
Beyond the preview
Go deeper on NCT04811469.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04811469.